Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009 10. ↵ 11. ↵ 12. ↵ 13. ↵ 14. ↵ 15. ↵ 16. ↵ 17. ↵ 18. ↵ 19
[doi.org]
Abstract It is unclear whether patients with nondiabetic kidney disease benefit from angiotensin-converting enzyme inhibitor (ACEI) therapy when they are at low risk for disease
[jasn.asnjournals.org]
(Grade: weak recommendation, low-quality evidence) ACP recommends that clinicians select pharmacologic therapy that includes either an angiotensin-converting enzyme inhibitor
[ncbi.nlm.nih.gov]